Get the Stockscreener App
2.42
16.35%
0.34
Pre-market:
2.73
0.31
+12.81%
Serina Therapeutics Inc stock is traded at $2.42, with a volume of 506.97K.
It is up +16.35% in the last 24 hours and down -25.54% over the past month.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
See More
Previous Close:
$2.08
Open:
$2.15
24h Volume:
506.97K
Relative Volume:
14.16
Market Cap:
$25.81M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+26.50%
1M Performance:
-25.54%
6M Performance:
-56.40%
1Y Performance:
-49.48%
1-Day Range:
$2.12
$2.43
1-Week Range:
$1.9201
$2.43
52-Week Range:
$1.7101
$7.92
Serina Therapeutics Inc Stock (SER) Company Profile
Name
Serina Therapeutics Inc
Sector
Industry
Phone
(256) 327-9630
Address
601 GENOME WAY, HUNTSVILLE
Compare SER with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
2.42 | 22.18M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Serina Therapeutics Inc Stock (SER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | H.C. Wainwright | Buy |
Serina Therapeutics Inc Stock (SER) Latest News
What is the fair value of Serina Therapeutics Inc. stock now2026 world cup usa national team third place match top scorers high defensive line winner prediction insights - ulpravda.ru
Breakout Zone: Is Bolt Biotherapeutics Inc stock vulnerable to regulatory risksTrade Entry Report & Expert-Curated Trade Recommendations - moha.gov.vn
Growth Value: Why Serina Therapeutics Inc stock attracts global investorsWeekly Market Report & Consistent Income Trade Recommendations - moha.gov.vn
Published on: 2025-12-31 12:01:21 - bollywoodhelpline.com
Trade Recap: Can Serina Therapeutics Inc 2BO stock sustain breakout momentumQuarterly Market Summary & Accurate Technical Buy Alerts - moha.gov.vn
Moreadith of Serina Therapeutics sells shares worth $15,167 By Investing.com - Investing.com India
Moreadith of Serina Therapeutics sells shares worth $15,167 - Investing.com
Serina Therapeutics CSO Sells Shares - TradingView — Track All Markets
Serina Therapeutics (SER) Chief Scientific Officer option exercise and share sale - Stock Titan
Aug Sectors: Why Serina Therapeutics Inc. stock is considered a top pickIPO Watch & Safe Capital Growth Plans - Улправда
Will Serina Therapeutics Inc. stock top growth indexes2025 Fundamental Recap & Community Verified Trade Alerts - Улправда
Why Serina Therapeutics Inc. stock is in analyst buy zoneJuly 2025 Short Interest & Community Trade Idea Sharing - Улправда
Ideas Watch: Why Serina Therapeutics Inc. stock attracts global investors2025 Price Action Summary & Long-Term Capital Growth Ideas - moha.gov.vn
Is Serina Therapeutics Inc. stock cheap at current valuationJuly 2025 Volume & Short-Term Trading Alerts - Улправда
Will Serina Therapeutics Inc. stock deliver better than expected guidanceWall Street Watch & AI Powered Market Trend Analysis - DonanımHaber
Will Serina Therapeutics Inc. (2BO) stock sustain uptrend momentum2025 Stock Rankings & AI Forecast Swing Trade Picks - DonanımHaber
Will Serina Therapeutics Inc. stock continue dividend increasesInsider Selling & Community Verified Swing Trade Signals - DonanımHaber
Why Serina Therapeutics Inc. stock appeals to dividend seekers2025 Earnings Surprises & Low Risk Investment Opportunities - Улправда
Aug Fed Impact: Will Serina Therapeutics Inc. stock enhance shareholder valueEarnings Risk Summary & Weekly High Potential Alerts - DonanımHaber
Options Flow: Why Serina Therapeutics Inc. stock is favored by top institutionsIPO Watch & Advanced Swing Trade Entry Alerts - ulpravda.ru
Why Serina Therapeutics Inc. stock is favored by top institutionsSell Signal & Reliable Intraday Trade Alerts - Улправда
Why Serina Therapeutics Inc. stock is considered a top pick2025 Key Lessons & High Accuracy Trade Signal Alerts - Улправда
Serina Therapeutics (SER) CSO sells 3,227 shares after option exercise - Stock Titan
Officer Moreadith Sells 3,227 ($9.6K) Of Serina Therapeutics Inc [SER] - TradingView — Track All Markets
Serina Therapeutics (SER) CSO reports 1,700-share option-related trades filing - Stock Titan
Serina Therapeutics Earnings Notes - Trefis
Serina Therapeutics CSO Moreadith sells $11,519 in stock By Investing.com - Investing.com South Africa
Serina Therapeutics CSO Moreadith sells $11,519 in stock - Investing.com
Officer Moreadith Sells 3,555 ($11.5K) Of Serina Therapeutics Inc [SER] - TradingView — Track All Markets
Serina Therapeutics (SER) Chief Scientific Officer reports 3,555-share option exercise and sale - Stock Titan
Serina Therapeutics Holds 2025 Annual Stockholders Meeting - MSN
Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry - The Manila Times
Serina Therapeutics (SER) chief scientific officer reports stock option trades - Stock Titan
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program - The Manila Times
Serina Therapeutics (NYSE American: SER) responds to FDA clinical hold, targets Q1 2026 SER-252 Phase 1b start - Stock Titan
Serina Therapeutics Submits Response to FDA for SER-252 Program - TradingView — Track All Markets
Serina Therapeutics (NYSE: SER) files complete FDA hold response for SER-252 Parkinson's program - Stock Titan
Is Serina Therapeutics Inc. stock a defensive play amid uncertaintyWall Street Watch & Verified Momentum Watchlists - Newser
Will Serina Therapeutics Inc. stock sustain bullish trend into 2025Earnings Miss & Fast Gain Stock Trading Tips - Newser
How strong is Serina Therapeutics Inc. stock earnings growthJuly 2025 Action & Fast Exit and Entry Strategy Plans - Newser
How Serina Therapeutics Inc. stock moves in volatile trading sessionsWeekly Profit Recap & Fast Entry Momentum Trade Alerts - Newser
How Serina Therapeutics Inc. (2BO) stock valuation compares with sectorM&A Rumor & Weekly High Conviction Ideas - Newser
Will Serina Therapeutics Inc. stock profit from fiscal stimulusCEO Change & Verified Short-Term Plans - Newser
Serina Therapeutics CSO Moreadith sells $23k in shares By Investing.com - Investing.com Canada
Why Serina Therapeutics Inc. (2BO) stock benefits from AI revolutionMarket Risk Summary & Capital Efficient Trading Techniques - Newser
Will Serina Therapeutics Inc. stock hit analyst forecastsJuly 2025 Levels & Verified Swing Trading Watchlist - Newser
Why Serina Therapeutics Inc. stock is favored by hedge funds2025 Pullback Review & Risk Controlled Daily Plans - Newser
Why Serina Therapeutics Inc. stock appears on watchlistsJuly 2025 Decliners & Low Risk High Reward Ideas - Newser
Serina Therapeutics Inc Stock (SER) Financials Data
There is no financial data for Serina Therapeutics Inc (SER). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
28.63%
Cap:
|
Volume (24h):